** Brokerage Leerink Partners raises price target of healthcare conglomerate CVS Health CVS.N to $86 from $83
** New PT implies a 29% upside to the stock's last close
** Brokerage says that the Health Care Benefits business is the main source of earnings growth and that CVS is well-positioned here, especially in Medicare Advantage
** Brokerage believes that some risks remain in Medicaid and ACA/Obamacare plans, but overall, CVS has less exposure to these problem areas compared to peers
** CVS Caremark, its pharmacy benefits management unit is expected to perform well, driven by specialty drugs and higher usage - Leerink
** Leerink says prescription sales in the retail pharmacy segment is strong and CVS is gaining share, though sales of other products are still weak because consumers are spending less
** As of last close CVS stock up 48.5% YTD
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com))
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。